CRIS Current Research Information System

CLISSA, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.558
AS - Asia 2.277
EU - Europa 1.968
AF - Africa 198
Continente sconosciuto - Info sul continente non disponibili 112
SA - Sud America 111
OC - Oceania 2
Totale 7.226
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.457
SG - Singapore 657
CN - Cina 624
VN - Vietnam 520
GB - Regno Unito 458
IT - Italia 436
SE - Svezia 297
DE - Germania 213
HK - Hong Kong 126
IN - India 106
FR - Francia 99
RU - Federazione Russa 90
BR - Brasile 70
IE - Irlanda 58
CA - Canada 57
NL - Olanda 56
KR - Corea 55
GR - Grecia 48
TG - Togo 46
BD - Bangladesh 45
SC - Seychelles 43
ZA - Sudafrica 41
FI - Finlandia 35
NG - Nigeria 34
EE - Estonia 30
UA - Ucraina 30
JP - Giappone 22
JO - Giordania 21
AT - Austria 20
BE - Belgio 19
CH - Svizzera 19
HR - Croazia 19
CI - Costa d'Avorio 18
BG - Bulgaria 17
AR - Argentina 15
MX - Messico 15
PH - Filippine 13
IR - Iran 10
MY - Malesia 10
EC - Ecuador 8
ES - Italia 7
PL - Polonia 7
TH - Thailandia 7
TM - Turkmenistan 7
CR - Costa Rica 6
ID - Indonesia 6
MU - Mauritius 6
PK - Pakistan 6
TR - Turchia 6
BB - Barbados 5
CO - Colombia 5
IL - Israele 5
LT - Lituania 5
SA - Arabia Saudita 5
GT - Guatemala 4
TW - Taiwan 4
AZ - Azerbaigian 3
IQ - Iraq 3
JM - Giamaica 3
LB - Libano 3
OM - Oman 3
PE - Perù 3
PY - Paraguay 3
UY - Uruguay 3
UZ - Uzbekistan 3
VE - Venezuela 3
CY - Cipro 2
EG - Egitto 2
ET - Etiopia 2
HN - Honduras 2
KE - Kenya 2
KG - Kirghizistan 2
NI - Nicaragua 2
QA - Qatar 2
TN - Tunisia 2
AL - Albania 1
AU - Australia 1
BS - Bahamas 1
BZ - Belize 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GI - Gibilterra 1
GY - Guiana 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MQ - Martinica 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SO - Somalia 1
SV - El Salvador 1
SX - ???statistics.table.value.countryCode.SX??? 1
TT - Trinidad e Tobago 1
Totale 7.115
Salva come PNG Salva come JPEG
Città #
Singapore 479
Southend 418
Ashburn 274
Chandler 197
Fairfield 180
Santa Clara 150
Hefei 138
San Jose 128
Hong Kong 121
Bologna 117
Beijing 94
Houston 93
Woodbridge 92
Wilmington 90
Ho Chi Minh City 86
Dong Ket 82
Seattle 80
Princeton 79
Ann Arbor 78
Hanoi 77
Cambridge 67
Milan 65
Council Bluffs 63
Dublin 58
Boardman 54
Lomé 46
New York 45
Seoul 44
Westminster 40
Padova 37
Nanjing 36
Lauterbourg 33
Los Angeles 32
Helsinki 29
Saint Petersburg 27
Abeokuta 26
Medford 24
Amman 21
Frankfurt am Main 21
Abidjan 18
Brussels 18
Buffalo 18
Jinan 18
Berlin 17
Sofia 17
Changsha 16
Phoenix 16
Shenyang 16
Tokyo 16
Turin 16
Bern 15
Dallas 15
Montreal 15
Jiaxing 14
Redwood City 14
Vienna 14
Bengaluru 13
Da Nang 13
Shanghai 13
Athens 12
Haiphong 12
Hebei 12
Munich 12
Nanchang 12
Redondo Beach 12
Rome 12
Florence 11
Jacksonville 11
Toronto 11
Bremen 10
Chicago 10
Tappahannock 10
Mexico City 9
Orem 9
Tianjin 9
Amsterdam 8
Dearborn 8
Grafing 8
Guangzhou 8
Haikou 8
Norwalk 8
San Diego 8
Valsamoggia 8
Falkenstein 7
Hangzhou 7
São Paulo 7
Zhengzhou 7
Falls Church 6
Kuala Lumpur 6
Mahé 6
North York 6
Tallinn 6
Tongling 6
Turku 6
Bridgetown 5
Brooklyn 5
Bühl 5
Davao City 5
Istanbul 5
Johannesburg 5
Totale 4.471
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 368
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 296
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 288
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 281
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 278
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 259
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 244
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 238
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 229
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 227
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 225
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 219
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 213
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 213
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 210
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 206
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 196
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 192
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 190
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 183
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 183
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 176
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 170
Nuclear inositide signaling in myelodysplastic syndromes. 163
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 154
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 152
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 149
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 140
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 137
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 137
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 135
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 134
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 134
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 128
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 113
null 103
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study 92
null 71
Totale 7.226
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.737
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.737
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022631 0 0 0 86 78 48 19 38 39 72 120 131
2022/2023881 72 127 43 114 73 65 31 92 144 9 73 38
2023/2024296 7 41 20 30 40 62 9 18 20 18 16 15
2024/2025832 36 69 71 49 173 50 53 31 3 54 52 191
2025/20262.149 193 211 170 139 246 97 227 86 393 214 81 92
2026/2027418 51 72 160 135 0 0 0 0 0 0 0 0
Totale 7.226